Suggested remit: To appraise the clinical and cost effectiveness of levodopa, carbidopa monohydrate and entacapone within its marketing authorisation for treating the symptoms of advanced Parkinson’s disease
Status Topic selection
Technology type Medicine
Decision Not selected
Reason for decision Not eligible for Health Technology Evaluation guidance
ID number 4005

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
20 July 2022 The NICE Topic Selection Oversight Panel (TSOP), met in June 2022 to carefully consider the suitability of this topic for a Technology Appraisal (TA). The panel concluded it would not be an efficient use of NHS resources to conduct an evaluation. The topic will be formally removed from the NICE work programme. Due to the non-selection, NHS England may consider the technology for routine commissioning – please see section 3.1 of the NHS England Procedural note: non submission of data to NICE for further information. Any request for consideration for routine commissioning needs to be submitted via a clinician; the Service Development Policy outlines the process.
11 July 2022 Topic selection. Change TS decision to deselected
03 May 2022 (10:00) Scoping workshop
15 March 2022 - 12 April 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
15 March 2022 In progress. Scoping commenced
15 March 2022 In progress. Scoping commenced
28 January 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on how we select topics for development, please see our page about topic selection